These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26759624)

  • 21. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR; Marzella N
    Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lansoprazole for maintenance of remission of erosive oesophagitis.
    Freston JW; Jackson RL; Huang B; Ballard ED
    Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC; Vakily M; Dixit T; Mulford D
    Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
    Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
    Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
    Parekh PJ; Oldfield EC; Johnson DA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
    Rimmani HH; Rustom LBO; Rahal MA; Shayto RH; Chaar H; Sharara AI
    Dig Dis; 2019; 37(3):188-193. PubMed ID: 30625462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.
    Wu JCY; Sheu BS; Wu MS; Lee YC; Choi MG
    J Neurogastroenterol Motil; 2020 Jan; 26(1):85-95. PubMed ID: 31597230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
    Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
    Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
    Vakily M; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?
    Tack J; Fass R
    Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():28-34. PubMed ID: 14725576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.